David Meeker: And I think all the questions and Dae Gon, your question, of course, sounds specifically, which we totally are sympathetic to and we have the same questions as we seek to understand — better understand this opportunity. All the diseases is — most diseases, including rare diseases, have some front loading as they go through development. There’s patients who are tracking this and expecting that moment of approval and looking to go on. So there’s always a bit of that front loading. I think what’s been incredibly reassuring about this opportunity in BBS is that, as we’ve now gone deeper into the launch in the fourth quarter, I think is a good standalone quarter in that sense. The demand is clearly there. And what we hope is, one is, yes, we continue to work to find more patients, which we’re doing and we’re doing successfully.
Second, as you build the system, meaning, you get more centers, more individual physicians who are writing prescription and taking interest, you begin to build an ecosystem which those patients who are seeking care and or think they might have BBS start to find us. And so that process will continue. And again, there’s nothing about the BBS opportunity to date. That doesn’t — that changes our view that this isn’t a very meaningful opportunity and ways to track some of the other well established well known examples of rare disease success stories. So we’ll keep you updated and try to give you as much insight as we can, but we are learning with you.
Dae Gon Ha: And then, David, what about the Xinvento, if there is any €“
David Meeker: Sorry. Yes, apologies for not be more specific. So we’re not going to reveal the modality that we’re chasing this morning, again, I think the unmet need here, there’s a tolerability issue with the current standard of care, there’s some safety issues related to the current standard of care and then we think there’s suboptimal efficacy. And so this solution we would hope would address all three of those. But again, stay tuned on the exact modality of the target.
Dae Gon Ha: Great. Thanks so much.
Operator: Please standby for our next question. Our next question comes from Whitney Ijem with Canaccord. Your line is now open.
Whitney Ijem: Hey, guys. Good morning. Another kind of I guess type of runway question for you on scripts. Are any early color on compliance rate or refill rate just as we think about that new prescription number you’re giving versus kind of total prescription headed into 2023?
Jennifer Chien: Sure. So at first in several different rare diseases in the past and one thing that was interesting to But if — and when the patients actually feel a different, while being on the drug, that tended to lead to a higher persistence, as well as a compliance rate. So when you think about a patient population, the hyperphagia here is a key factor. It’s something that just impacts them like really day to day, hour to hour. And feeling a list of that or relief of that was finally to the weight loss is something that they can feel in terms of benefit of being on drug. And so we have seen a very high compliance rate even with the daily injectable because of this. And once again, it’s due to the benefits that they receive.
From a discontinuation of persistence rate, it is early days, but I will say that we are quite happy just in terms of what we have seen. There was a lot of education on both the ACP as well as the patient side around expectations as well as ongoing engagement with our customers so that we could get our through the titration process and maintain them on drug. So I would say that the discontinuation rate is quite low and we’re very pleased with that.
